Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89.6M
-
Number of holders
-
4
-
Total 13F shares, excl. options
-
94.3K
-
Shares change
-
-72.3M
-
Total reported value, excl. options
-
$1.13M
-
Value change
-
-$812M
-
Number of sells
-
-166
-
Price
-
$11.27
Significant Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q3 2025
182 filings reported holding VERV - Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2025.
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) has 4 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.3K shares
of 89.6M outstanding shares and own 0.11% of the company stock.
Largest 10 shareholders include Greenland Capital Management LP (49.5K shares), DekaBank Deutsche Girozentrale (24K shares), Brooklyn Investment Group (17.4K shares), OSAIC HOLDINGS, INC. (3.34K shares), CWM, LLC (0 shares), Fortitude Family Office, LLC (0 shares), Farther Finance Advisors, LLC (0 shares), SIGNATUREFD, LLC (0 shares), HARBOR CAPITAL ADVISORS, INC. (0 shares), and LOS ANGELES CAPITAL MANAGEMENT LLC (0 shares).
This table shows the top 4 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.